Teva, MylanActavis, and Lupin announced the launch of Celecoxib Capsules, the generic version of Pfizer’s Celebrex.

Celebrex is a non-steroidal anti-inflammatory drug indicated for the relief of signs and symptoms of osteoarthritis, rheumatoid arthritis, juvenile rheumatoid arthritis, ankylosing spondylitis, acute pain, and for the treatment of primary dysmenorrhea. Celecoxib is believed to exert its anti-inflammatory, analgesic, and antipyretic activities through inhibition of prostaglandin synthesis, primarily via inhibition of cyclooxygenase-2 (COX-2).

RELATED: First Generic Versions of Celebrex Approved

Teva’s Celecoxib Capsules are available in 50mg and 400mg strengths in 60-count bottles; and 100mg and 200mg strengths in 100- and 500-count bottles.

For more information visit,, or